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Abstract:
As of 2017, vascular diseases contributed to 23.1% of all deaths in America. To address
the need for more effective and sustainable treatment options for these ailments, stem cell
differentiation and implantation has emerged as a viable alternative to standard bypass and graft
insertions. A completely autologous treatment can be achieved by extracting adult stem cells,
differentiating them into vascular smooth muscle cells (VSMCs), and then reimplanting these
cells at the affected tissue site. This study aims to investigate the efficiency of the VSMC
differentiation from human mesenchymal stem cells (hMSCs) by comparing 4 cell lines of
untreated hMSCs with 3 cell lines of hMSCs that have been grown in two differentiation
factors–platelet derived growth factor (PDGF) and transforming growth factor 𝛃-1 (TGF𝛃-1)–in
order to mature into VSMCs. The cell lines will be evaluated based on variations in RNA
expression. Total RNA will be isolated from the cell lines and subsequently sequenced. Raw data
will be analyzed using bioinformatic techniques to determine which genes are transcribed
significantly differently between hMSCs and hMSC-derived VSMCs. Total RNA is being
sequenced so that the transcription rates of all genes may be compared between cell lines;
however, expected outcomes of known hMSC and VSMC markers would include increased
transcription of CD 29/44/73/105 and decreased transcription of MYH11, ACTA2, and TAGLN
in hMSCs. Converse results would be expected in the hMSC-derived VSMCs. Elucidating the
specific variations in transcription levels between hMSCs and hMSC-derived VSMCs will lead
to the development of standardized chromatin immunoprecipitation sequencing (ChIP-Seq)
assays that can determine if post-treatment hMSCs have been successfully differentiated into
VSMCs, leading to accurate autologous stem cell treatments to various cardiovascular diseases.
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Introduction:
Background
Currently in the United States, cardiovascular diseases–which encompass both heart and
blood vessel-related ailments–are the highest cause of death in the general population (Benjamin
2019). Under typical circumstances, this category of diseases contributes to approximately a
quarter of all deaths; however, this percentage is only expected to rise due in part to a
corresponding increase in the aging population as well as a growth in the number of people being
diagnosed with diseases like diabetes that are comorbid to cardiovascular disease.
Stem cells are an invaluable component of tissue engineering based treatments for
injuries and diseases affecting complex vasculature. They allow for the realm of tissue
engineered vessels to be broadened by the fact that they can contribute to the angiogenesis of
simple capillary vessels without scaffolds or ECM to guide this regeneration. The inverse is not
true. The most effective means of involving stem cells in engineering vascular tissue is by
combining cells with varying levels of potency as these different types of cells have been shown
to contribute to vascular regeneration through a range of means including secreting
differentiation factors to induce surrounding stem and progenitor cells to differentiate and
exhibiting the ability to differentiate into cells located in all three layers of large vessels.
As various novel cellular therapies are investigated through clinical research and
eventually approved for use in medical treatments, studies must be concurrently conducted to
ensure that cell populations can be developed efficiently and inexpensively while maintaining
uniformity and fulfilling demand (Dwarshius 2017). Most cell therapies require that patients take
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several doses during the course of their treatment, and each dose typically contains a few billion
cells, bringing the total number of cells needed per patient per treatment up to ~ 1010 − 1012 cells.
With regards to human vasculature, many varieties of stem cells have been shown to be
capable of differentiating into both vascular endothelial cells (ECs) and smooth muscle cells
(SMCs) which are located in the tunica intima and tunica media of larger vessels, respectively
(Dimitrievska 2018; Lin 2017; Gui 2016; Patsch 2015; Guerin 2015). An example of a
successful application of cell therapy is the positive effect of human mesenchymal stem
cell-derived smooth muscle cells (hmSMCs) on abdominal aortic aneurysms, acute myocardial
infarction, and other expressions of cardiac disease (Swaminathan 2017; Gu 2017).
The research surrounding MSCs and their direct ability to differentiate into vascular cells
is disputed (Patsch 2015 Ge 2018). Despite this result, one of the studies focusing on MSCs
reported that, in vivo, undifferentiated MSCs secreted VEGF—a growth factor that can influence
other stem cells and progenitor cells to further differentiate into different vascular cells (Ge
2018). These results may indicate that a combination of stem cells with varying levels of potency
could be utilized for optimal in vivo a ngiogenesis.
For the purposes of this project, focus is placed on the ability of hMSCs derived from
human adipose tissue to differentiate into smooth muscle cells. It is the long-term goal of this
research that healthcare providers can begin conducting individual cardiac patient-centered care
by treating them with hmSMCs derived from their own stem cells and expanded to a viable dose
using human fibronectin-containing media. By obtaining stem cells from the patients themselves,
the risk of immunologically rejected VSMC implantation is greatly reduced as there are no
foreign biological or synthetic materials being introduced to the body.
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In order to confirm that smooth muscle cells created under various culture conditions
have characteristics consistent with native smooth muscle cells, multiple methods may be
employed to compare cellular genomes, proteomes, and metabolomes. By using total RNA
sequencing, it is possible to both ensure that cells differentiated from hMSCs are no longer
expressing typical hMSC gene products as well as affirming that they are expressing various
SMC gene markers. Additionally, this method can be used to verify that there is no significant
difference between hMSC-derived SMCs cultured in either fetal bovine serum (FBS) or
serum-free media (SFM).
Typically, in order to establish the control presence of hMSCs, cells are tested for the
upregulation of markers such as CD73 and CD105 (Singh 2016; Lemcke 2017). In the past, the
Rao lab has also used the presence of CD29 and CD44 as additional hMSC markers.
In contrast, typical SMC markers that have been used for genomic confirmation include:
ACTA2, TAGLN, and MYH11 (Brun 2015; Ji 2016). The Rao lab has also used SM22𝜶 in
previous proteomic studies to indicate the successful differentiation of SMCs from hMSCs.

Objectives
The main objective of this study is to use total RNA sequencing to confirm that
post-differentiation cells exhibiting changes in phenotype that are characteristic with smooth
muscle cells are also up- or down-regulating specific SMC gene markers.
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Expected Outcomes
It is expected that there will be a significant difference in the expression and transcription
levels of various genes between the MSC samples and SMC samples. If this is not the case, then
that implies that although there may have been a discrepancy between the phenotype of these cell
populations and their genotype. However, if there are specific gene products that are found to be
transcribed at a higher rate in one of the cells types than the other, then these findings can be
used to further confirm differentiation of SMCs from hMSCs in future research.
Among the known gene products that are expected to be relatively upregulated in hMSCs
are those associated with protein markers CD 29/44/73/105. Conversely, gene products expected
to be upregulated relatively higher in the SMCs compared to the hMSCs in this study are those
corresponding to protein markers MYH11, ACTA2, and TAGLN

Materials and Methods:
Cell Culture
For this experiment, undifferentiated and differentiated cells from four cell lines were
used to compare the variations in genetic transcription between human stem cells and stem
cell-derived smooth muscle cells. Table 1 in the Appendix specifies the cell lines used, their
origins, the differentiation treatment used, and the sample number assigned to each cell type.
All cells were seeded in T-75 flasks and incubated at 37℃ with 5% O2 . Media for all
flasks was changed every 2-3 days, and flasks were passaged once they reached approximately
80% confluency or greater. Undifferentiated samples 2, 4, and 6 were fed using human
fibroblast-containing SFM, and differentiated samples 3, 5, and 7 were fed using serum-free
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differentiation media to maintain their differentiated state. Flasks containing ATCC3 cells were
fed using a specific ATCC3 differentiation media.

Cell Count
In order to collect enough genetic material to yield substantial RNA analysis, each
sample must have between 105 − 107 cells, which is approximately the number of cells that a
T-75 flask holds once the culture has reached total confluency. To confirm that the number of
cells was in the range needed to continue to RNA isolation, cell counting was performed.
First, media containing cell waste and dead cells was aspirated from the flasks under a
hood and disposed of in a sterile container. 2 mL PBS was added to each flask and aspirated to
wash the cells. This step was then repeated. 3.5-5 mL of trypsin was added to each flask to
detach and lift the cells from the bottom of the flasks. The flasks were then incubated at 37℃ at
5% O2 for 5 minutes. During this time, one 10 mL centrifuge tube and one microcentrifuge tube
were labelled to correspond with each flask. 10 µL of trypan blue was added to each
microcentrifuge tube.
After 5 minutes, the flasks were physically agitated, observed under a microscope to
ensure that the cells have detached, and then placed back under the hood. At this time, the
trypsin/cell solution was removed from each flask and placed in an appropriately labelled 10 mL
centrifuge tube. An equal amount of trypsin neutralizing solution (3.5-5 mL) was added to each
flask to collect any stray cells, and then added to the corresponding 10 mL centrifuge tube. At
this time, the flasks were inverted several times to distribute the cells equally in the ~7mL-10mL
of solution. Then, 10 µL of the cell solution was removed from each 10 mL centrifuge tube and
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added to the corresponding microcentrifuge tube. The 10 mL centrifuge tubes were then
centrifuged for 4 minutes at 12,000 RPM or ~16,000 G.
While the cell solutions were being centrifuged, a pipette was used to mix the contents of
each microcentrifuge tube. For each sample, 1 µL of the trypan blue cell solution was added to
each side of a hemocytometer that was then loaded into an automated cell counter, which
provided a cell count once the user input the total volume of the cell solution.

Sample Preparation
Once cells were counted and all of the samples were centrifuged, the solution was
removed from the centrifuge tubes, taking care not to disturb the cell pellet at the bottom of the
10 mL centrifuge tube. 1 mL of trizol was added to each tube, cells were resuspended, and
samples were moved to microcentrifuge tubes before being incubated for 5 minutes at room
temperature.
Following room temperature incubation, 200 µl of chloroform was added to each tube
and tubes were then vortexed for 15 seconds. Samples were again incubated at room temperature
for 2-3 minutes before being centrifuged at 12,000 RPM, or ~16,000 G, for 15 minutes at 2-8°C.
After this phase separation sequence, the supernatant from each sample was transferred to
autoclaved centrifuge tubes before proceeding to the Qiagen RNeasy RNA Isolation protocol.

RNA Isolation
Once isolated, the aqueous samples from the previous step were centrifuged at 23°C for 5
min at 5000 G, or ~6500 RPM. Following centrifugation, the supernatants were discarded, and
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350 µL of RLT buffer was added per tube. The tubes were then vortexed on auto for 2-5 minutes
to incorporate the RLT buffer with the cells. The mixtures were then transferred to purple Qia
Shredder Spin Columns and centrifuged for 2 minutes at 21,000 G, or ~13,500 RPM.
350 µL of supernatant was collected from the Spin Columns following centrifugation and
pipetted into clear gDNA eliminator columns. These samples in these columns were then
centrifuged again at 10,000 G, or ~9,500 RPM, for 30 seconds. 350 µL of 70% ethanol was then
added to flow-through the gDNA eliminator column and mixed with the existing buffer solution.
Then, 700 µL from each sample was added to pink RNeasy columns before discarding the
flow-through from each of these columns. The filters were saved and placed back into their
respective columns before 700 µL of RW1 buffer was added. Following this addition, the
columns were centrifuged again at 10,000 G, or ~9,500 RPM, for only 15 seconds.
After centrifugation the flow-through was discarded once more, the filter was replaced
back in the column, and 500 µL of RPE buffer was added to each column. The samples were
again centrifuged at 10,000 G, or ~9,500 RPM, for 15 seconds, and again the flow-through was
discarded.
500 µL of RPE buffer was added to each sample once more before samples were
centrifuged at 10,000 G, or ~9,500 RPM, for 2 minutes and flow-through was subsequently
discarded. The filters were then transferred to collection tubes and centrifuged for a penultimate
time at 21,000 G, or ~13,500 RPM, for 1 minutes. The filters were again removed from the
collection tubes and placed in Eppendorf tubes. It is important to note that this set-up is
intentional despite the inability to fully close the Eppendorf tubes when the filters are present.
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Finally, 40 µL RNAse-free water was pipetted straight onto each filter and the tubes with
filters attached were centrifuged at 10,000 G, or ~9,500 RPM, for 1 minutes. Filters could then
be discarded, and the Eppendorf tubes were stored in a -80°C freezer until RNA quality could be
assessed.

RNA Concentration and Quality Determination

Samples were removed from the -80°C freezer and placed immediately on ice with a
bottle of RNAse-free water in a large beaker before being transported to a plate reader. The plate
itself was prepared by being sprayed with RNAse Away and wiped down with sterile Kimwipes.
Before loading samples in the plate reader, the Gen 5 program was opened and parameters were
selected to determine the concentration and quality of RNA samples. The final step in preparing
the program was selecting the A1 and A2 squares on the grid and marking them as blanks to
calibrate the plate reader.
Once the program had been set up, 2 µL of RNAse-free water was pipetted using a
filtered PCR pipette in each of the sample positions that corresponded with the grid locations
selected during the previous step. The option to “Read Blanks” was selected before carefully
closing and placing the plate inside the plate reader and pressing “OK.” If the A1 and A2 spots
on the program’s grid displayed green dots, then the plate reader had been calibrated
appropriately and sample concentrations and quality could be determined. However, if the A1
and A2 spots displayed red dots, then the machine had not been calibrated correctly, and the
plate needed to be cleaned before loading another set of blanks and repeating the above steps.

12
Following calibration, the 14 grid spots on the program needed to be labelled with the
names of the samples that would correspond to their positions on the plate, keeping in mind that
duplicate trials are to be performed on each sample. After preparing the computer program, 2 µL
per sample per trial were loaded in their predetermined position on the plate again using filtered
PCR pipettes. The plate was then closed carefully and placed inside the plate reader before
selecting “Read Sample” on the program. The subsequent data was then exported to an Excel
spreadsheet and emailed to the researcher after which the plate was cleaned with RNAse Away
and Kimwipes before replacing it to its storage case.
Concentrations were reported in ng/µL and the 260/280 value, which indicates sample
purity, was reported as a unitless number. Ideal 260/280 numbers should be in the range of
1.9-2.1.
In addition to checking the sample concentration and quality using a plate reader
available for use by the researcher, samples were also delivered to another on-campus facility
that assessed these characteristics as well using a nucleic acid tapestation. Concentrations were
reported in ng/µL like the plate reader; however, the quality was reported in the form of an RNA
Integrity Number (RIN) where good quality samples are considered to have a RIN that is greater
than 7.

Sample Transportation
In order to sequence the total RNA, samples needed to be shipped to the Novogene
genomic sequencing lab in Davis, California on the University of California at Davis campus.
The seven microcentrifuge tubes containing the seven individual samples were packed in a large
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conical tube with Kimwipes to ensure that the microcentrifuge tubes would not be displaced
during travel. This large conical tube was then placed in ~5 lbs of dry ice packed in a styrofoam
box that was taped shut and shipped in a cardboard container.

Results:
Unfortunately, due to delays caused by the ongoing COVID-19 pandemic, there have
been some delays retrieving total RNA sequencing data from Novogene. This has not, however,
interfered with the concentration and quality data collected from two separate sources that will
be outlined below.
Based on the results gathered from the plate reader, which can be found in Table 2 in the
Appendix, only samples 1 and 3 had an average 260/280 number that was not within the
accepted range of 1.9-2.1. Interestingly, there was a clear pattern between the concentrations of
undifferentiated cells and differentiated cells of each cell line that demonstrated much higher
concentrations of RNA amongst the undifferentiated samples, samples 2, 4, and 6, that ranged
from 28.9 ng/µL to 99.7 ng/µL. Conversely, the differentiated samples 1, 3, 5, and 7 all had an
RNA concentration between 5-6 ng/µL with only one outlier that was 15.7 ng/µL.
The tapestation delivered somewhat similar results to the ones outlined above. Exact
values for the tapestation tests are located in Table 3. With regards to the quality, the RIN for all
of the samples was reported to be exactly 10.0, well above the 7.0 threshold needed to proceed
with further testing. These results contradict with the results from the plate reader that
determined based on the 260/280 that samples 1 and 3 were not of a high enough standard to
move forward with future testing. Concentration values derived from the tapestation test were
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remarkably similar to those received from the plate reader. Again, undifferentiated samples 2, 4,
and 6 exhibited RNA concentrations in the range of 41.2 ng/µL to 121 ng/µL, whereas
differentiated samples 1, 3, 5, and 7 all reported RNA concentrations between 5-6 ng/µL with the
same outlier at 18.1 ng/µL.

Analysis and Discussion:
Conclusion
As mentioned above in the Results section of this paper, due to delays related to the
COVID-19 pandemic, RNA sequencing data for this project has been delayed and cannot be
discussed at the present moment.
However, the concentration data alone indicates that there are significant differences
between the overall transcription levels of the undifferentiated and differentiated cell samples.
When the concentration data derived from the plate reader was subject to an independent
one-tailed equal variance t-test comparing the average concentration of the undifferentiated
samples 2, 4, and 6 with the differentiated samples 1, 3, 5, and 7, a p-value 0.017 was returned.
The same test administered on the same sample groups using data from the tapestation also
yielded a p-value of 0.011. Both of these values are well under the threshold of p<0.05 that
indicates statistical significance. This confirms that there is a quantifiable difference in the total
RNA concentration levels of these two samples. Because all procedures for this project were
performed on all samples simultaneously through the period of this research, it is most likely that
these differences are due to variations in DNA transcription that would lead to an overall lower
level of RNA present in differentiated SMC samples than in undifferentiated MSC samples.
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Future Directions
The first and foremost step that will be taken in this project is to incorporate the delayed
RNA sequencing data to complete this honors thesis. This will include bioinformatic analysis to
determine if there are specific genes that are more highly expressed in either differentiated or
undifferentiated samples. It is expected that among the more highly transcribed genes in
undifferentiated MSCs will be genes associated with CD 29/44/73/105 proteins, and in
differentiated SMCs, genes corresponding to MYH11, ACTA2, SM22ɑ and TAGLN proteins
will be more highly transcribed.
Beyond this research project, the information derived from the RNA sequencing data
obtained through these samples may be able to help create a standardized chromatin
immunoprecipitation sequencing (ChIP-Seq) assay that could be used to confidently assess
whether SMCs differentiated from MSCs reflect genotypic as well as phenotypic characteristics
of native smooth muscle cells.
Eventually, it is the long-term goal of this lab to create stem cell-based treatments for
various cardiovascular ailments and diseases that are safe for patient use, consistent between
treatment doses, and easily producible by clinicians and healthcare providers.
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Appendix:
Table 1: Sample numbers, cell lines, differentiation status, and origin tissue
Sample Number Cell Line Cell Type

Origin

1

ATCC3

Differentiated with
PDGF+TGF𝛃-1

2

41035

Undifferentiated

Human adipose tissue

3

41035

Differentiated with
PDGF+TGF𝛃-1

Human adipose tissue

4

82726

Undifferentiated

Human adipose tissue

5

82726

Differentiated with
PDGF+TGF𝛃-1

Human adipose tissue

6

99375

Undifferentiated

Human adipose tissue

99375

Differentiated with
PDGF+TGF𝛃-1

Human adipose tissue

7

hMSCs derived from 21-year
old vietnamese male

Table 2: Sample characteristics derived from the plate reader. Concentrations reported in ng/µL
and quality reported in unitless 260/280 numbers.
Sample Number Concentration (ng/µL) 260/280
1

6.6

1.75

2

28.9

1.94

3

6.6

1.77

4

99.7

2.02

5

15.7

1.96

6

50.2

2.03

7

5.3

1.91
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Table 3: Sample characteristics derived from the on-campus tapestation. Concentrations reported
in ng/µL and quality reported in unitless RIN.
Sample Number Concentration (ng/µL) RIN
1

5.1

10.0

2

41.2

10.0

3

6.1

10.0

4

121.0

10.0

5

18.1

10.0

6

63.0

10.0

7

5.1

10.0

